Abstract
2013 e7 mum tolerated dose was approached at 80 to 100 mg due to symptoms of chest discomfort and dyspnea. These results reveal a good safety margin to the highest dose selected for Phase 3 (20 mg). Disclosure of Interest: M. Hoch: Shareholder of Actelion Pharmaceuticals Ltd, employee of: Actelion Pharmaceuticals Ltd. D. D'Ambrosio: Shareholder of Actelion Pharmaceuticals Ltd, employee of Actelion Pharmaceuticals Ltd. D. Wilbraham: Employee of Quintiles Drug Research Unit at Guy's Hospital. P. Brossard: Shareholder of Actelion Pharmaceuticals Ltd, employee of Actelion Pharmaceuticals Ltd. J. Dingemanse: Shareholder of Actelion Pharmaceuticals Ltd, employee of Actelion Pharmaceuticals Ltd.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
